FDA authorizes updated COVID-19 booster
The Food and Drug Administration (FDA) has authorized the use of updated Moderna and Pfizer vaccines to protect against the Omicron variant of COVID-19 for use as a single booster dose at least two months following a primary or booster vaccination. Read the release.
CDC updates vaccination guidance for immunocompromised
The Centers for Disease Control and Prevention (CDC) has released interim clinical considerations for use of bivalent vaccines. Read the guidance. The CDC has also issued an updated vaccination schedule for people who are moderately or severely immunocompromised.
NIH updates guidance on monoclonal antibodies
The National Institute of Health’s (NIH) COVID-19 Treatment Guidelines Panel has updated their recommendations for the use of anti-SARS-CoV-2 monoclonal antibodies. Read the latest recommendations from NIH.
Updated COVID-19 Summary of Evidence
The OPTN Ad Hoc Disease Transmission Advisory Committee completed its quarterly update of the SARS-CoV-2 Summary of Evidence on Aug. 22, 2022. This version includes current information on Omicron sublineages BA.4/BA.5 as well as the most recent literature on SARS-CoV-2 and its effect on transplant.
The latest data on organ donation and transplant in the U.S.
Find high-level data on transplants, deceased donors recovered, patients added to the waitlist and patients temporarily moved to inactive waitlist status.
NIH updates guidance for people who are immunocompromised
- NIH’s COVID-19 Treatment Guidelines Panel has updated their recommendations for people who are immunocompromised. Read the latest recommendations from NIH.
FDA advises repeat testing following a negative COVID-19 test
- The FDA advises repeat testing following a negative test result, to reduce the risk an infection may be missed (false negative result) and to help prevent people from unknowingly spreading the virus to others. Read the safety communication.
Summer 2022 regional meetings in-person
- To continue maximizing accessibility for attendees, a virtual option will remain available as we return to meeting in-person. Although we are over halfway through the cycle, the virtual option means that you can attend any of the meetings that work with your schedule. Learn more and register for your region’s meeting.